NIA SBIR-FUNDED JUVENA THERAPEUTICS TRANSLATION OF POWERFUL PROTEINS INTO TRANSFORMATIVE THERAPEUTICS
2024
Juvena Therapeutics and the Impact of SBIR Funding
publication
Author Information
Author(s): O’Connell Jeremy
Primary Institution: Juvena Therapeutics, Inc.
Conclusion
Juvena Therapeutics has successfully advanced its biotech efforts and raised significant funding due to the support from NIA SBIR funding.
Supporting Evidence
- Juvena Therapeutics received NIA SBIR funding in 2021.
- The company has raised close to $60 million in venture capital funding since receiving SBIR support.
- Juvena's platform screens proteins to restore tissue homeostasis.
Takeaway
Juvena Therapeutics is using special proteins to help heal tissues, and they got money to help them grow their business.
Methodology
Juvena uses an AI platform to analyze and engineer proteins for therapeutic use.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website